These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. CD133 is essential for glioblastoma stem cell maintenance. Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586 [TBL] [Abstract][Full Text] [Related]
49. ER stress and UPR activation in glioblastoma: identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation. Peñaranda-Fajardo NM; Meijer C; Liang Y; Dijkstra BM; Aguirre-Gamboa R; den Dunnen WFA; Kruyt FAE Cell Death Dis; 2019 Sep; 10(10):690. PubMed ID: 31534165 [TBL] [Abstract][Full Text] [Related]
50. Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma. Chen G; Kong J; Tucker-Burden C; Anand M; Rong Y; Rahman F; Moreno CS; Van Meir EG; Hadjipanayis CG; Brat DJ Cancer Res; 2014 Aug; 74(16):4536-48. PubMed ID: 24947043 [TBL] [Abstract][Full Text] [Related]
51. Girdin maintains the stemness of glioblastoma stem cells. Natsume A; Kato T; Kinjo S; Enomoto A; Toda H; Shimato S; Ohka F; Motomura K; Kondo Y; Miyata T; Takahashi M; Wakabayashi T Oncogene; 2012 May; 31(22):2715-24. PubMed ID: 22020337 [TBL] [Abstract][Full Text] [Related]
52. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme. Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134 [TBL] [Abstract][Full Text] [Related]
53. Extracellular vesicle-mediated transfer of CLIC1 protein is a novel mechanism for the regulation of glioblastoma growth. Setti M; Osti D; Richichi C; Ortensi B; Del Bene M; Fornasari L; Beznoussenko G; Mironov A; Rappa G; Cuomo A; Faretta M; Bonaldi T; Lorico A; Pelicci G Oncotarget; 2015 Oct; 6(31):31413-27. PubMed ID: 26429879 [TBL] [Abstract][Full Text] [Related]
54. Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma. Satterlee AB; Dunn DE; Lo DC; Khagi S; Hingtgen S Neuro Oncol; 2019 Dec; 21(12):1552-1564. PubMed ID: 31420675 [TBL] [Abstract][Full Text] [Related]
55. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Kaluzova M; Bouras A; Machaidze R; Hadjipanayis CG Oncotarget; 2015 Apr; 6(11):8788-806. PubMed ID: 25871395 [TBL] [Abstract][Full Text] [Related]
56. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
57. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408 [TBL] [Abstract][Full Text] [Related]
58. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755 [TBL] [Abstract][Full Text] [Related]
59. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. Silber J; Lim DA; Petritsch C; Persson AI; Maunakea AK; Yu M; Vandenberg SR; Ginzinger DG; James CD; Costello JF; Bergers G; Weiss WA; Alvarez-Buylla A; Hodgson JG BMC Med; 2008 Jun; 6():14. PubMed ID: 18577219 [TBL] [Abstract][Full Text] [Related]
60. Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. Sun T; Patil R; Galstyan A; Klymyshyn D; Ding H; Chesnokova A; Cavenee WK; Furnari FB; Ljubimov VA; Shatalova ES; Wagner S; Li D; Mamelak AN; Bannykh SI; Patil CG; Rudnick JD; Hu J; Grodzinski ZB; Rekechenetskiy A; Falahatian V; Lyubimov AV; Chen YL; Leoh LS; Daniels-Wells TR; Penichet ML; Holler E; Ljubimov AV; Black KL; Ljubimova JY Cancer Res; 2019 Mar; 79(6):1239-1251. PubMed ID: 30659021 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]